Teal Health Builds At-Home Cervical Cancer Screening

Teal Health is a San Francisco women’s health company building a coordinated at-home pathway for cervical cancer screening. Its Teal Wand is an FDA-authorized vaginal self-collection device used with prescription-based virtual care, laboratory testing, secure results, and follow-up navigation.

CEO and co-founder Kara Egan leads Teal Health with co-founder Avnesh “Ave” Thakor, MD, PhD, an interventional radiologist and translational scientist. Sarah Rose serves as COO. The company was founded in 2020 to make cervical screening more accessible for people who face barriers to a traditional clinic visit.

Teal Health matters now because the product has crossed several difficult gates at once. The company has clinical validation, FDA De Novo authorization, nationwide availability, and $45M in total reported funding. Its next test is operational: turning a mailed collection kit into routine preventive care without losing patients between prescription, fulfillment, laboratory processing, results, and follow-up.

About Teal Health

Teal Health describes its mission as giving women the tools and resources to make empowered, informed decisions about their health, beginning with cervical cancer screening. The company’s model is broader than a consumer device. An eligible patient completes a virtual visit, receives a prescribed Teal Wand kit, collects a sample at home, mails it to a laboratory for high-risk HPV testing, and receives results through Teal Health’s platform.

The company’s strategic insight is that the uncomfortable part of cervical screening is not the only barrier. Time away from work, appointment availability, childcare, travel, trauma, and the coordination required after an abnormal result can all reduce participation. Teal Health moves collection into the home while keeping prescribing, laboratory analysis, clinical review, and follow-up inside a connected care pathway.

That distinction matters. A kit can improve convenience, but convenience alone does not complete a screening. Teal Health’s product is the operating chain around the Teal Wand, not merely the wand itself.

Clinical Evidence Behind the Teal Wand

The Teal Wand received FDA De Novo authorization in May 2025 and became available nationwide in January 2026. The authorization covers an at-home vaginal self-collection pathway for cervical cancer screening, with eligibility, prescription, laboratory testing, result review, and appropriate follow-up still required.

The peer-reviewed SELF-CERV study indexed by PubMed recruited 609 screening-eligible participants across 16 U.S. sites. Among 582 evaluable paired samples, self-collected samples showed 95.2% positive percentage agreement for high-risk HPV and 95.8% clinical sensitivity for high-grade cervical dysplasia. Relative sensitivity was equivalent to clinician collection in the evaluable study population.

Those results give Teal Health a stronger foundation than the usual digital-health promise of making an old workflow prettier on a phone. The company is asking patients and clinicians to trust a different collection setting, so clinical performance is not a supporting detail. It is the admission ticket.

Leadership, Funding, and Market Position

Kara Egan founded Teal Health after experience across health-tech investing, software, and company building. Avnesh Thakor brings clinical and translational-science expertise. Sarah Rose’s operating role becomes especially relevant as Teal Health expands a system that touches telehealth, logistics, laboratories, reimbursement, and care navigation.

Teal Health raised an $8.8M seed round in 2023 and an additional $10M seed financing in 2025. In September 2026, the company announced a $22M Series A led by .406 Ventures. Emerson Collective, managed by Yosemite, Forerunner, and Serena Ventures returned, while MPower Partners joined as a new investor. The financing brought Teal Health’s company-reported total funding to $45M.

Teal Health says it has screened thousands of women nationally, with 59% of users previously underscreened, and reports a 4.95/5 average rating from thousands of users. Those figures are company-reported, but they clarify the market thesis: a meaningful share of screening demand exists among people the traditional workflow has not served consistently.

Why Reimbursement and Distribution Matter

Updated federal preventive-services guidance is expected to require most health plans to cover self-collected cervical cancer screening and necessary follow-up without patient cost sharing for plan years beginning in 2027. Applicability can vary by plan type, but the change could move at-home collection from a direct-purchase option toward a reimbursed preventive-care channel.

That transition changes Teal Health’s competitive challenge. Consumer awareness still matters, but payer integration, provider coordination, billing, fulfillment, laboratory operations, and reliable follow-up become the real distribution layer. The company plans to expand partnerships with payers, health systems, employers, providers, and brands while widening direct-purchase access.

The competitive field includes established clinic-based screening workflows and other self-collection approaches. Teal Health’s differentiator is its attempt to package collection, virtual care, logistics, testing, results, and navigation into one experience. Its durable advantage will depend on whether that integrated pathway performs reliably across different coverage arrangements and clinical settings.

Hiring Momentum as an Operating Signal

Teal Health’s careers page says the company is hiring across functions as it builds the next phase of women’s healthcare. Its live job board currently lists roles in health-system partnerships, lifecycle marketing, and revenue-cycle management.

That mix is more revealing than a generic growth announcement. A director of health-system partnerships points toward institutional distribution. A lifecycle-marketing role points toward sustained patient engagement. Revenue-cycle leadership points toward the unglamorous mechanics of reimbursement. Together, the openings show a company preparing to make clinical access work inside the American healthcare payment system, where every good idea eventually meets a billing code and a spreadsheet.

What Teal Health Signals for Preventive Care

Teal Health reflects a broader shift in healthcare: the home is becoming a legitimate point of clinical collection, but only when the surrounding evidence and care infrastructure are strong enough. The Teal Wand reduces the location burden of screening. Teal Health still has to prove that patients receive clear results and timely follow-up at national scale.

The company’s opportunity is to reach people who postpone or avoid screening without separating convenience from clinical rigor. If Teal Health can integrate with payers, health systems, employers, providers, and laboratories while preserving a coherent patient experience, at-home self-collection could become a normal part of cervical cancer prevention rather than a niche alternative.

That is the real company spotlight. Teal Health is not selling a mailer. It is building the operating layer between a validated sample, a trusted result, and the next clinical action.